Celgene Corporation – Product Pipeline Review – 2015

“Celgene Corporation – Product Pipeline Review – 2015

Summary

Global Markets Direct’s, ‘Celgene Corporation – Product Pipeline Review – 2015’, provides an overview of the Celgene Corporation’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Celgene Corporation’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides brief overview of Celgene Corporation including business description, key information and facts, and its locations and subsidiaries
– The report reviews current pipeline of Celgene Corporation’s human therapeutic division and enlists all their major and minor projects
– The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
– Special feature on out-licensed and partnered product portfolio
– The report summarizes all the dormant and discontinued pipeline projects
– Latest company statement
– Latest news and deals relating to the Celgene Corporation’s pipeline products

Reasons to buy

– Evaluate Celgene Corporation’s strategic position with total access to detailed information on its product pipeline
– Assess the growth potential of Celgene Corporation in its therapy areas of focus
– Identify new drug targets and therapeutic classes in the Celgene Corporation’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
– Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
– Develop strategic initiatives by understanding the focus areas of Celgene Corporation and exploit collaboration and partnership opportunities
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Plan mergers and acquisitions effectively by identifying the most promising pipeline of Celgene Corporation
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Explore the dormant and discontinued projects of Celgene Corporation and identify potential opportunities in those areas
– Avoid Intellectual Property Rights related issues”

“Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 8
Celgene Corporation Snapshot 9
Celgene Corporation Overview 9
Key Information 9
Key Facts 9
Celgene Corporation – Research and Development Overview 10
Key Therapeutic Areas 10
Celgene Corporation – Pipeline Review 17
Pipeline Products by Stage of Development 17
Pipeline Products – Monotherapy 18
Pipeline Products – Partnered Products 19
Partnered Products/Combination Treatment Modalities 20
Pipeline Products – Out-Licensed Products 22
Out-Licensed Products/Combination Treatment Modalities 23
Celgene Corporation – Pipeline Products Glance 24
Celgene Corporation – Late Stage Pipeline Products 24
Pre-Registration Products/Combination Treatment Modalities 24
Phase III Products/Combination Treatment Modalities 25
Celgene Corporation – Clinical Stage Pipeline Products 26
Phase II Products/Combination Treatment Modalities 26
Phase I Products/Combination Treatment Modalities 27
Celgene Corporation – Early Stage Pipeline Products 28
Preclinical Products/Combination Treatment Modalities 28
Discovery Products/Combination Treatment Modalities 29
Celgene Corporation – Drug Profiles 30
apremilast 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
lenalidomide 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
paclitaxel albumin bound 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
amrubicin hydrochloride 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
azacitidine 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
pomalidomide 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
romidepsin 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CC-11050 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CC-220 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
cenplacel-L 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
GI-6301 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
mongersen 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
PDA-002 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
spebrutinib besylate 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
AG-221 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
CC-223 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ARRY-382 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
CC-115 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CC-122 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
CC-90001 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CC-90002 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CC-90003 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CTP-730 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
EPZ-5676 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Stem Cell Therapy for Hematological Malignancies and Non-Malignant Disorders 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ABI-013 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Antibody for Oncology 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
AVL-181 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
AVL-192 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
CC-0730671 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
CC-2142 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
CC-509 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CC-539 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
CNX-1351 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
IMiDxl 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Small Molecules for Cancer and Inflammation 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Small Molecules for Undisclosed Indication 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Antibody for Undisclosed Indication 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
CC-0739623 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
CC-2141 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CSC-1 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Drug to Inhibit Kinase for Inflammation 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Drugs for Hematology and Oncology 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
EPIpros-1 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
EPIpros-2 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Small Molecule to Inhibit Brutons Tyrosine Kinase for Inflammation 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Small Molecules for Inflammation 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecules for Inflammation and Cancer 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Small Molecules for Malaria 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Celgene Corporation – Pipeline Analysis 101
Celgene Corporation – Pipeline Products by Target 101
Celgene Corporation – Pipeline Products by Route of Administration 103
Celgene Corporation – Pipeline Products by Molecule Type 104
Celgene Corporation – Pipeline Products by Mechanism of Action 105
Celgene Corporation – Recent Pipeline Updates 107
Celgene Corporation – Dormant Projects 140
Celgene Corporation – Discontinued Pipeline Products 142
Discontinued Pipeline Product Profiles 142
CC-1088 142
satraplatin 142
Celgene Corporation – Company Statement 143
Celgene Corporation – Locations And Subsidiaries 145
Head Office 145
Other Locations & Subsidiaries 145
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 151
Disclaimer 152″
“List of Tables
Celgene Corporation, Key Information 9
Celgene Corporation, Key Facts 9
Celgene Corporation – Pipeline by Indication, 2015 11
Celgene Corporation – Pipeline by Stage of Development, 2015 17
Celgene Corporation – Monotherapy Products in Pipeline, 2015 18
Celgene Corporation – Partnered Products in Pipeline, 2015 19
Celgene Corporation – Partnered Products/ Combination Treatment Modalities, 2015 20
Celgene Corporation – Out-Licensed Products in Pipeline, 2015 22
Celgene Corporation – Out-Licensed Products/ Combination Treatment Modalities, 2015 23
Celgene Corporation – Pre-Registration, 2015 24
Celgene Corporation – Phase III, 2015 25
Celgene Corporation – Phase II, 2015 26
Celgene Corporation – Phase I, 2015 27
Celgene Corporation – Preclinical, 2015 28
Celgene Corporation – Discovery, 2015 29
Celgene Corporation – Pipeline by Target, 2015 101
Celgene Corporation – Pipeline by Route of Administration, 2015 103
Celgene Corporation – Pipeline by Molecule Type, 2015 104
Celgene Corporation – Pipeline Products by Mechanism of Action, 2015 106
Celgene Corporation – Recent Pipeline Updates, 2015 107
Celgene Corporation – Dormant Developmental Projects,2015 140
Celgene Corporation – Discontinued Pipeline Products, 2015 142
Celgene Corporation, Other Locations 145
Celgene Corporation, Subsidiaries 145″
“List of Figures
Celgene Corporation – Pipeline by Top 10 Indication, 2015 11
Celgene Corporation – Pipeline by Stage of Development, 2015 17
Celgene Corporation – Monotherapy Products in Pipeline, 2015 18
Celgene Corporation – Partnered Products in Pipeline, 2015 19
Celgene Corporation – Out-Licensed Products in Pipeline, 2015 22
Celgene Corporation – Pipeline by Top 10 Target, 2015 101
Celgene Corporation – Pipeline by Top 10 Route of Administration, 2015 103
Celgene Corporation – Pipeline by Top 10 Molecule Type, 2015 104
Celgene Corporation – Pipeline Products by Top 10 Mechanism of Action, 2015 105″